Clinical trials as treatment option: Bioethics and health care disparities in substance dependency

Social Science and Medicine

Volumn 69, Issue 12, 2009, Pages 1784-1790

  Timmermans, Stefan ^a   McKay, Tara ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bioethics; Clinical trials; Human subjects; Pharmaceutical industry; Research ethics; Substance dependency; USA

Indexed keywords

AMFEBUTAMONE; METHAMPHETAMINE; MODAFINIL; PLACEBO;

DRUG USER; ETHICS; HEALTH CARE; PHARMACEUTICAL INDUSTRY; RESEARCH AND DEVELOPMENT;

ARTICLE; BIOETHICS; CLINICAL RESEARCH; CLINICAL TRIAL; COUNSELING; DRUG DEPENDENCE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE FACILITY; HEALTH CARE POLICY; HUMAN; MEDICAL PROFESSION; OBSERVATIONAL STUDY; PATIENT CARE; PRIMARY MEDICAL CARE; PROFIT; SUBSTANCE ABUSE;

BIOETHICAL ISSUES; CLINICAL TRIALS, PHASE III AS TOPIC; CONFLICT OF INTEREST; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; INTERVIEWS AS TOPIC; METHAMPHETAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH SUBJECTS; RESEARCHER-SUBJECT RELATIONS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

NORTH AMERICA; UNITED STATES;

EID: 71749100226     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2009.09.019     Document Type: Article

References (51)

1. Abraham J. Drug trials and evidence bases in international regulatory context. BioSocieties 2 1 (2007) 41-56
2. Anspach R. Deciding who lives: Fateful choices in the intensive care nursery (1993), University of California Press, Berkeley, CA
3. Appelbaum P.S., Roth L.H., and Lidz C. The therapeutic misconception: informed consent in psychiatric research. International Journal of Law and Psychiatry 5 3-4 (1982) 319-329
4. Barr A.M., Panenka W.J., MacEwan W.G., Thornton A.E., Lang D.J., Honer W.G., et al. The need for speed: an update on methamphetamine addiction. Journal of Psychiatry and Neuroscience 31 5 (2006) 301-313
5. Berg M. Rationalizing medical work: Decision support techniques and medical practices (1997), MIT Press, Cambridge, MA
6. Borders T.F., Booth B.M., Han X., Wright P., Leukefeld C., Falck R.S., et al. Longitudinal changes in methamphetamine and cocaine use in untreated rural stimulant users: racial differences and the impact of methamphetamine legislation. Addiction 103 (2008) 800-808
7. Braunholtz D.A., Edwards S.J.L., and Lilford R.J. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". Journal of Clinical Epidemiology 54 (2001) 217-224
8. Cartwright N. Are RCTs the gold standard?. BioSocieties 2 1 (2007) 11-20
9. Chambliss D.F. Beyond caring: Hospitals, nurses, and the social organization of ethics (1996), University of Chicago Press, Chicago
10. Compton W.M., Thomas Y.F., Stinson F.S., and Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States. Archives of General Psychiatry 64 May (2007) 566-576
11. Cunningham J., and Liu L.-M. Impact of methamphetamine precursor chemical legislation, a suppression policy, on the demand for drug treatment. Social Science & Medicine 66 (2008) 1463-1473
12. DeNavas-Walt C., Proctor B.D., and Smith J. Income, poverty, and health insurance coverage in the United States: 2006, Current population reports (2007), U.S. Census Bureau, Washington, D.C.
13. Donovan D.M., and Wells E.A. 'Tweaking 12-step': the potential role of 12-step self-help group involvement in methamphetamine recovery. Addiction 102 Suppl. 1 (2007) 121-129
14. Easter M.M., Henderson G.E., Davis A.M., Churchill L.R., and King N.M.P. The many meanings of care in clinical research. Sociology of Health and Illness 28 6 (2006) 695-712
15. Elkashef A., Rawson R.A., Smith E., Pearce V., Flammino F., Campbell J., et al. The NIDA methamphetamine clinical trials group: a strategy to increase clinical trials research capacity. Addiction 102 Suppl. 1 (2007) 107-113
16. Elliott C., and Abadie R. Exploiting a research underclass in phase 1 clinical trials. New England Journal of Medicine 358 22 (2008) 2316-2317
17. Epstein S. Impure science: AIDS, activism, and the politics of knowledge (1996), University of California Press, Berkeley
18. Epstein S. Inclusion: The politics of difference in medical research (2007), University of Chicago Press, Chicago
19. Farmer P. Pathologies of power: Health, human rights, and the new war on the poor (2005), University of California Press, Berkeley
20. Fatseas M., and Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Current Psychiatry Reports 9 5 (2007) 358-364
21. Fisher E.S., Goodman D.C., Skinner J.S., and Wennberg J.E. Tracking the care of patients with severe chronic illness: The Dartmouth atlas of health care 2008 (2008), The Dartmouth Institute for Health Policy and Clinical Practice
22. Fisher J.A. Practicing research ethics: private-sector physicians and pharmaceutical clinical trials. Social Science & Medicine 66 12 (2008) 2495-2505
23. Fishman J.R. Manufacturing desire: the commodification of female sexual dysfunction. Social Studies of Science 34 2 (2004) 187-218
24. Grossman J., and MacKenzie F.J. The randomized controlled trial: gold standard or merely standard. Perspectives in Biology and Medicine 48 4 (2005) 516-534
25. Henderson G.E., Churchill L.R., Davis A.M., Easter M.M., Grady C., Joffe S., et al. Clinical trials and medical care: defining the therapeutic misconception. PLOS Medicine 4 11 (2007) 1735-1738
26. Himmelstein D.U., Warren E., Thorne D., and Woolhandler S. Illness and injury as contributors to bankruptcy. Health Affairs(W5) (2005) 65-73
27. Joffe S., Cook E.F., Cleary P.D., Clark J.W., and Weeks J.C. Quality of informed consent in cancer clinical trials: a cross sectional survey. The Lancet 358 9295 (2001) 1772-1777
28. Katz J. Human experimentation and human rights. Saint Louis University Law Journal 38 1 (1993) 7-54
29. Kimmelman J. The therapeutic misconception at 25: treatment, research and confusion. Hastings Center Report 37 6 (2007) 36-42
30. King N.M.P. Defining and describing benefit appropriately in clinical trials. Journal of Law, Medicine, and Ethics 28 (2000) 332-343
31. Lakoff A. Pharmaceutical reason: Knowledge and value in global psychiatry (2005), Cambridge University Press, Cambridge
32. McLellan T.A., Lewis D.C., O'Brien C.P., and Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. Journal of American Medical Association 284 13 (2000) 1689-1695
33. de Melo-Martin I., and Ho A. Beyond informed consent: the therapeutic misconception and trust. British Medical Journal 34 3 (2008) 202-205
34. Miller F.G., and Brody H. What makes placebo-controlled trials unethical?. American Journal of Bioethics 2 2 (2002) 3-9
35. Miller F.G., and Rosentstein D.L. The therapeutic orientation to clinical trials. New England Journal of Medicine 348 14 (2003) 1383-1386
36. Mumola C., and Karberg J.C. Drug use and dependency, state and federal prisoners, 2004 (2007), U.S. Department of Justice, Bureau of Justice Statistics, Washington, D.C.
37. NDIC. National drug threat assessment (2008), National Drug Intelligence Center
38. Ng R. Drugs: From discovery to approval (2004), Wiley-Liss, New York
39. Nicosia N., Pacula R.L., Kilmer B., Lundberg R., and Chiesa J. The economic cost of methamphetamine use in the United States, 2005 (2009), RAND: Drug Policy Research Center, Santa Monica, CA
40. Orr J. Panic diaries: A genealogy of panic disorder (2006), Duke University Press, Durham
41. Owen F. The speed limit: The highs and lows of meth (2007), St. Martin's Press, New York
42. Pace C., Miller F.G., and Danis M. Enrolling the uninsured in clinical trials: an ethical perspective. Critical Care Medicine 31 3 (2003) S121-S125
43. Peppercorn J.M., Weeks J.C., Cook E.F., and Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363 9405 (2004) 263-270
44. Petryna A. Clinical trials offshored: on private sector science and public health. BioSocieties 2 1 (2006) 21-40
45. Roll J.M. Contingency management: an evidence-based component of methamphetamine use disorder treatments. Addiction 102 Suppl. 1 (2007) 114-140
46. SAMHSA. Results from the 2006 national survey on drug use and health: National findings (2007), Office of Applied Studies, Rockville, MD
47. Saxon A.J., and McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology and Therapeutics 108 (2005) 119-128
48. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Social Science & Medicine 66 (2008) 1909-1914
49. Timmermans S., and Tavory I. Advancing ethnographic research through grounded theory practice. In: Bryant A., and Charmaz K. (Eds). Handbook of grounded theory (2007), Sage, London 493-513
50. Winslow B.T., Voorhees K.I., and Pehl K.A. Methamphetamine abuse. American Family Physician 76 8 (2007) 1169-1174
51. Worrall J. What evidence in evidence-based medicine. Philosophy of Science 69 (2002) S316-S330